|1.||Nizhevich, A A: 2 articles (01/2011 - 01/2009)|
|2.||Shcherbakov, P L: 2 articles (01/2011 - 01/2009)|
|3.||Uspenskiĭ, Iu P: 2 articles (01/2009 - 01/2002)|
|4.||Yuen, M F: 2 articles (10/2007 - 06/2001)|
|5.||Chan, C K: 2 articles (10/2007 - 06/2001)|
|6.||Deng, Feng: 2 articles (06/2006 - 10/2003)|
|7.||Sun, Hongzhe: 2 articles (06/2006 - 10/2003)|
|8.||Kung, N N: 2 articles (07/2001 - 06/2001)|
|9.||Eshraghian, M R: 2 articles (03/2001 - 03/2000)|
|10.||Malekzadeh, R: 2 articles (03/2001 - 03/2000)|
08/01/1989 - "The ulcer healing efficacy of tripotassium dicitrato bismuthate is unlikely to be related to a gastric anti-protease effect."
05/01/1986 - "The ulcer healing efficacy of De-Nol may be related to this decline in the proteolytic action of gastric juice, but is unlikely to be because of a quantitative change in mucus, or in acid secretion."
01/01/1987 - "Studies on the gastroprotective and ulcer-healing effects of colloidal bismuth subcitrate."
01/01/2008 - "All these properties characterize de-nol as a single universal preparation for the treatment of erosive ulcers in the gastrointestinal tract."
12/01/1998 - "In a rat model of gastric ulceration, BTBT was comparable to, and CDTB was significantly less effective than colloidal bismuth subcitrate in healing cryoprobe-induced ulcers. "
|2.||Duodenal Ulcer (Curling's Ulcer)
02/01/1990 - "Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori."
08/01/1996 - "After 4 weeks of treatment median concentrations of 3.4 micrograms/L or less were reported amongst 1210 duodenal ulcer patients receiving this new chemical entity, while mean concentrations of 5.1 micrograms/L (plasma) and 12.3 micrograms/L (blood) have been reported in two studies of patients receiving tripotassium dicitrato bismuthate 120 mg q.d.s. "
01/01/1993 - "A clinico-morphological study was made of processes in the gastro-duodenal mucosa during treatment of duodenal ulcer by de-nol. "
03/27/1985 - "Thirty-five patients with duodenal ulcers were treated with tripotassium dicitrato-bismuthate (TDB) in a double-blind, double-dummy endoscopically controlled trial. "
10/01/1983 - "A double-blind trial using 51 outpatients was aimed at comparing the effectiveness of colloidal bismuth subcitrate (C.B.S.) in tablet and liquid form in the healing of duodenal ulcer. "
|3.||Stomach Ulcer (Gastric Ulcer)
05/01/1982 - "Controlled clinical trials have shown that tripotassium dicitrato bismuthate healed duodenal and gastric ulcers significantly better than placebo. "
07/01/1982 - "Gastric ulcer healing with tripotassium dicitrato bismuthate and subsequent relapse."
05/01/1982 - "Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat."
05/28/1977 - "Thirty-seven outpatients with benign gastric ulcers proved by endoscopy were randomized and treated with tripotassium dicitrato-bismuthate (TDB) and a placebo for four weeks. "
01/01/1990 - "It is concluded that the efficacy of DE-NOL is comparable to that of RN, although some minor differences in healing rates were observed: these being in favour of DE-NOL in the gastric ulcer patients and in favour of RN in the duodenal ulcer patients, respectively. "
|4.||Peptic Ulcer (Peptic Ulcers)
09/01/1991 - "Colloidal bismuth subcitrate is as effective as the H2-receptor antagonists in peptic ulcer. "
01/01/2007 - "[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer]."
01/01/1988 - "The healing properties of colloidal bismuth subcitrate (CBS) on peptic ulcer are well established and several studies have shown that healing with CBS is associated with a lower relapse rate than that produced by H2-receptor antagonists. "
01/01/2008 - "In treatment 60 patients with duodenal and stomach peptic ulcer in composition standard eradication therapy was used de-nol. "
01/01/2008 - "[Clinical response to de-nol in peptic ulcer patients]."
01/20/1992 - "An infection was eradicated in 97.4% of patients treated with De-Nol. "
10/01/1989 - "Four-week therapy with De Nol eradicated Campylobacter pylori in 60% of treated children, and reduced infection in the next 25%. "
05/01/1992 - "This study suggests that Helicobacter pylori infection is associated with physicochemical changes in the gastric mucus with a reduction in its capacity to concentrate colloidal bismuth subcitrate. "
06/01/1997 - "pylori infection received the combination of bismuth subcitrate 240 mg b.d., furzolidone 100 mg q.d.s. "
01/01/1993 - "Sixteen patients with HP infection were treated with DeNol 330 mg/day for 4 weeks. "
|1.||bismuth tripotassium dicitrate (bismuth subcitrate)